Recent insider selling at Y-mAbs Therapeutics may indicate i...
Recent insider selling at Y-mAbs Therapeutics may indicate insiders believe shares are overpriced. The absence of insider purchases in the past year and low insider ownership warrant caution.
Selling US$1.9m Of Stock Was Lucrative Decision For Y-mAbs Therapeutics Insiders
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4563Followers
0Following
9970Visitors
Follow